Abstract
Non-melanoma skin cancers (NMSCs) are the most commonly diagnosed cancers in Canadians. Although basal cell carcinoma (BCC) is approximately four to five times more common (80% of non-melanoma skin cancers) than squamous cell carcinoma (SCC) (20% of non-melanoma skin cancers), the incidence of both tumor types continues to rise despite increasing awareness of the risk factors. BCC is characterized by local and sometimes disfiguring invasiveness; however, metastasis is rare, occurring in less than 0.05% of cases. SCCs, in contrast, are responsible for the majority of deaths from non-melanoma skin cancers as they have a higher metastatic potential (~5% at 5 years). There are a variety of treatment options for both BCC and SCC including surgical excision, Mohs micrographic surgery, topical therapy, local destructive techniques, and radiation therapy.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Canadian Cancer Society: Non-melanoma skin cancer statistics. Available at http://www.cancer.ca/en/cancer-information/cancer-type/skin-non-melanoma/statistics/?region=on.
Guenther LC, Barber K, Searles GE, Lynde CW, et al. Non-melanoma skin cancer in Canada chapter 1: introduction to the guidelines. J Cutan Med Surg. 2015;19(3):205–15.
Mortenson MM, Herne K, Hymes SR, Cormier JN. Chapter 4 nonmelanoma skin cancer. In: Feig BW, Ching CD, editors. The MD Anderson surgical oncology handbook. 5th ed. Philadelphia: Lippincott Williams and Wilkins; 2012. p. 117–26.
Keohane SG, Proby CM, Newlands C, Motley RJ. The new 8th edition of TNM staging and its implications for skin cancer: a review by the British Association of Dermatologists and the Royal College of Pathologists, U.K. Br J Dermatol. 2018;179(4):824–8.
Madan V, Lear JT, Szeimies RM. Non-melanoma skin cancer. Lancet. 2010;375(9715):673–85.
Wong CSM, Strange RC, Lear JT. Basal cell carcinoma. BMJ. 2003;327:794–8.
Rubin AI, Chen EH, Ratner D. Basal-cell carcinoma. N Engl J Med. 2005;353:2262–9.
Perkins JL, Liu Y, Mitby PA, et al. Nonmelanoma skin cancer in survivors of childhood and adolescent cancer: a report from the childhood cancer survivor study. J Clin Oncol. 2005;23:3733–41.
Karagas MR, Nelson HH, Zens MS, et al. Squamous cell and basal cell carcinoma of the skin in relation to radiation therapy and potential modification of risk by sun exposure. Epidemiology. 2007;18:776–84.
Barber K, Searles GE, Vender R, et al. Non-melanoma skin cancer in Canada chapter 2: primary prevention of non-melanoma skin cancer. J Cutan Med Surg. 2015;19(3):216–26.
Verkouteren JAC, Ramdas KHR, Wakkee M, Nijsten T. Epidemiology of basal cell carcinoma: scholarly review. Br J Dermatol. 2017;177(2):359–72.
Alam M, Ratner D. Cutaneous squamous-cell carcinoma. N Engl J Med. 2001;344(13):975–83.
NCCN Clinical Practice Guidelines in Oncology: Basal Cell Skin Cancer. Version 1.2019, August 31, 2018 [online]. Available from URL: http://www.nccn.org/professionals/physician_gls/pdf/nmsc.pdf.
NCCN Clinical Practice Guidelines in Oncology: Squamous Cell Skin Cancer. Version 2.2019, October 31, 2018 [online]. Available from URL: http://www.nccn.org/professionals/physician_gls/pdf/squamous.pdf.
Boeta-Angeles L, Bennett RG. Features associated with recurrence (basal cell carcinoma). In: Miller SJ, Maloney ME, editors. Cutaneous oncology pathophysiology, diagnosis, and management. Malden: Blackwell Science; 1998. p. 646–56.
Haas AF. Features associated with metastasis (squamous cell carcinoma). In: Miller SJ, Maloney ME, editors. Cutaneous oncology, pathophysiology, diagnosis, and management. Malden: Blackwell Science; 1998. p. 500–5.
Clayman GL, Lee JJ, Holsinger FC, et al. Mortality risk from squamous cell skin cancer. J Clin Oncol. 2005;23:759–65.
Rowe DE, Carroll RJ, Day CL Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol. 1992;26:976–90.
Thompson AK, Kelley BF, Prokop LJ, et al. Risk factors for cutaneous squamous cell carcinoma recurrence, metastasis, and disease-specific death: a systematic review and meta-analysis. JAMA Dermatol. 2016;152(4):419–28.
Randle HW. Basal cell carcinoma. Identification and treatment of the high-risk patient. Dermatol Surg. 1996;22:255–61.
Rieger KE, Linos E, Egbert BM, Swetter SM. Recurrence rates associated with incompletely excised low-risk nonmelanoma skin cancer. J Cutan Pathol. 2010;37:59–67.
Rowe DE, Carroll RJ, Day CL Jr. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol. 1989;15:315–28.
Ulrich C, Kanitakis J, Stockfleth E, Euvrard S. Skin cancer in organ transplant recipients-where do we stand today? Am J Transplant. 2008;8:2192–8.
Brantsch KD, Meisner C, Schonfisch B, et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol. 2008;9:713–20.
Zioty D, Guenther LC, Sapijaszko M, et al. Non-melanoma skin cancer in Canada chapter 4: management of basal cell carcinoma. J Cutan Med Surg. 2015;19(3):239–48.
Sapijaszko M, Zioty D, Bourcier M, et al. Non-melanoma skin cancer in Canada chapter 5: management of squamous cell carcinoma. J Cutan Med Surg. 2015;19(3):249–59.
Samarasinghe V, Madan V. Nonmelanoma skin cancer. J Cutan Aesthet Surg. 2012;5:3–10.
Brodland DG, Zitelli JA. Surgical margins for excision of primary cutaneous squamous cell carcinoma. J Am Acad Dermatol. 1992;27:241–8.
Wolf DJ, Zitelli JA. Surgical margins for basal cell carcinoma. Arch Dermatol. 1987;123:340–4.
Good LM, Miller MD, High WA. Intralesional agents in the management of cutaneous malignancy: a review. J Am Acad Dermatol. 2011;64(2):413–22.
Kirby JS, Miller CJ. Intralesional chemotherapy for nonmelanoma skin cancer: a practical review. J Am Acad Dermatol. 2010;63(4):689–702.
Murray C, Sivajohanathan D, Hanna T, et al. Patient indications for Mohs micrographic surgery. Toronto: Cancer Care Ontario; 2018. Program in Evidence-Based Care Guideline No.:8–11.
Ross AS, Schmults CD. Sentinel lymph node biopsy in cutaneous squamous cell carcinoma: a systematic review of the English literature. Dermatol Surg. 2006;32:1309.
Renzi C, Caggiati A, Mannooranparampil TJ, et al. Sentinel lymph node biopsy for high risk cutaneous squamous cell carcinoma: case series and review of the literature. Eur J Surg Oncol. 2007;33:364.
Fahradyan A, Howell AC, Wolfswinkel EM, et al. Updates on the management of non-melanoma skin cancer (NMSC). Healthcare (Basel). 2017;5(4):E82. https://doi.org/10.3390/healthcare5040082.
Matthey-Giè ML, Boubaker A, Letovanec I, et al. Sentinel lymph node biopsy in nonmelanoma skin cancer patients. J Skin Cancer. 2013;2013:267474. https://doi.org/10.1155/2013/267474.
Lipson EJ, Lilo MT, Ogurtsova A, et al. Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade. J Immunother Cancer. 2017 Mar 21;5:23.
Cannon JGD, Russell JS, Kim J, et al. A case of metastatic basal cell carcinoma treated with continuous PD-1 inhibitor exposure even after subsequent initiation of radiotherapy and surgery. JAAD Case Rep. 2018;4(3):248–50.
Migden MR, Rischin D, Schmults CD, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018;379(4):341–51.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Lim, D.W. et al. (2020). Non-melanoma Skin Cancer. In: Wright, F., Escallon, J., Cukier, M., Tsang, M., Hameed, U. (eds) Surgical Oncology Manual. Springer, Cham. https://doi.org/10.1007/978-3-030-48363-0_19
Download citation
DOI: https://doi.org/10.1007/978-3-030-48363-0_19
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-48362-3
Online ISBN: 978-3-030-48363-0
eBook Packages: MedicineMedicine (R0)